Estrogen Receptor Agonist Market size was valued at USD 4.3 Billion in 2023 and is expected to exceed USD 11.01 Billion by the end of 2036, expanding at over 7.5% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of estrogen receptor agonist is evaluated at USD 4.59 Billion. This rise in market demand is anticipated to be driven by the growing prevalence of cardiovascular disease. According to the World Health Organization, with about 17.9 million deaths per year, cardiovascular diseases (CVDs) are the major cause of death globally. Hence, in order to treat this the demand for different treatments is growing among which estrogen receptor agonist is most preferred. Additionally, it has been proven to be one of the safer treatments for cardiovascular diseases.
Furthermore, women who are in their post-menopausal period are usually given estrogen receptor agonist treatment since they suffer various consequences such as a decline in the concentration of sex steroid hormones in the blood owing to a decline of ovary function. By 2030, the post-menopausal women are projected to reach 1.2 billion, globally.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
7.5% |
|
Base Year Market Size (2023) |
USD 4.3 Billion |
|
Forecast Year Market Size (2036) |
USD 11.01 Billion |
|
Regional Scope |
|
Route of Administration (Oral, Parental)
Estrogen receptor agonist market from the oral segment is anticipated to garner the highest revenue by the end of 2036. This segment growth is estimated to boost on account of its cost efficiency. Since parenteral drugs must be sterile and isotonic, the oral pharmaceuticals on the market are less expensive, which results in financial savings for the patient. Moreover, oral medication gets absorbed at a faster rate. Hence, they are most preferred.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies)
The hospital pharmacies segment in the estrogen receptor agonist market is set to have noteworthy growth over the forecast period. Most of estrogen receptor agonist drugs are prescribed by the doctors. Hence, the pharmacies attached to the hospitals are estimated to satisfy the growing demand for this medication.
Our in-depth analysis of the global market includes the following segments:
|
Product Type |
|
|
Indication Type |
|
|
Route of Administration |
|
|
Distribution Channel |
|
APAC Market Statistics
The Asia Pacific estrogen receptor agonist market is set to have the highest growth by the end of 2036, backed by the growing geriatric population in this region. In Asia and the Pacific region, one in four persons is expected to be older than 60 by 2050. Moreover, this transition is expected to happen relatively quickly in several nations, such as the People's Republic of China, Sri Lanka, Thailand, and Viet Nam. Hence, the demand for estrogen receptor agonist is poised to grow. Old people are prone to various diseases such as cardiovascular disease, asthma, and more. Hence, in order to treat or prevent the growth of disease, the market is estimated to grow.
North American Market Forecast
The North America estrogen receptor agonist market is projected to have significant growth over the forecast period. The market in this region is poised to grow on account of rising cases of cancer.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?